Trial Profile
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Sovleplenib (Primary)
- Indications Chronic lymphocytic leukaemia; Cutaneous B-cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Proof of concept
- Sponsors Hutchison MediPharma; HUTCHMED
- 05 Apr 2024 According to a HUTCHMED media release, company announces that results from this study will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2024,on April 5 to 10, 2024 in San Diego, California.
- 08 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 22 Feb 2023 Planned End Date changed from 1 Aug 2024 to 1 Jan 2026.